New kids in the block: The role of FasL and Fas in kidney damage

Journal of Nephrology

Volumn 12, Issue 3, 1999, Pages 150-158

  Ortiz, Alberto ^a,b   Lorz, Corina ^a   Egido, Jesús ^a  

^a Fundación Jiménez Díaz   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Apoptosis; Fas; FasL; Kidney

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; PROSTACYCLIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL ACTIVATION; CHEMOTAXIS; FIBROBLAST; GENE EXPRESSION; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY INJURY; KNOCKOUT GENE; KNOCKOUT MOUSE; LEUKOCYTE; MESANGIUM CELL; MOUSE; NONHUMAN; POINT MUTATION; PROTEIN CROSS LINKING; RAT; REVIEW;

EID: 0032778935     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-9.
2. Ortiz A, Gonzalez Cuadrado S, Lorz C, Egido J. Apoptosis in renal diseases. Front Biosci 1996; 1: D30-47.
3. Savill J. Apoptosis and renal injury. Curr Opin Nephrol Hypertens 1995; 4: 263-9.
4. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
5. Ortiz A, Gonzalez-Cuadrado S, Bustos C, Alonso J, Gómez-Guerrero C, López-Armada MJ, González E, Plaza JJ, Egido J. Tumor necrosis factor and glomerular damage. J Nephrol 1995; 8: 27-34.
6. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-13.
7. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-50.
8. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-6.
9. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997; 185: 1511-6.
10. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429-40.
11. Griffith TS, Brunner T, Fletcher M, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
12. French LE, Wilson A, Hahne M, Viard I, Tschopp J, MacDonald HR. Fas ligand expression is restricted to nonlymphoid thymic components in situ. J Immunol 1997; 159: 2195-202.
13. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nature Med 1996; 2: 1361-6.
14. Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med 1998; 4: 1377-82.
15. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
16. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest 1998; 102: 1682-9.
17. Boonstra JG, van der Woude FJ, Wever PC, Laterveer JC, Daha MR, van Koaten C. Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol 1997; 8: 1517-24.
18. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Batstein D, Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
19. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-87.
20. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
21. Seino K, Iwabuchi K, Kayagaki N, Miyata R, Nagaoka I, Matsuzawa A, Fukao K, Yagita H, Okumura K. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161: 4484-8.
22. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287-92.
23. Biancone L, Martino AD, Orlandi V, Conaldi PG, Toniolo A, Camussi G. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 1997; 186: 147-52.
24. Canceicao-Silva F, Hahne M, Schroter M, Louis J, Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol 1998; 28: 237-45.
25. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugal T, Kitamura Y, Itoh N, Suda T, Nagah S. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-9.
26. Giordano C, Stassi G, De Maria R, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Patential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275: 960-3.
27. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkan KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996; 335: 1643-9.
28. Sakata K, Sakah A, Vela-Roch N, Espinosa R, Escalante A, Kang L, Nakabayashi T, Cheng J, Talal N, Dang H. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes. Eur J Immunol 1998; 28: 2648-60.
29. Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Okumura K, Yagita H. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 1997; 94: 3914-9.
30. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577-82.
31. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714-7.
32. Ortiz-Arduan A, Danoff TM, Kalluri R, González-Cuadrado S, Karp SL, Elkon K, Egido J, Neilsan EG. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 1996; 241: F1193-201.
33. Thilenius AR, Braun K, Russell JH. Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Eur J Immunol 1997; 27: 1108-14.
34. Nishimura Y, Hirabayashi Y, Matsuzaki Y, Musette P, Ishii A, Nakal-chi H, Itloue T, Yonehara S. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997; 9: 307-16.
35. Fadeel B, Thorpe CJ, Yonehara S, Chiodi F. Anti-Fas IgGl antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Int Immunol 1997; 9: 201-9.
36. Nishimura-Morita Y, Nose M, Inoue T, Yonehara S. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Int Immunol 1997; 9: 1793-9.
37. González-Cuadrado S, Lorz C, García del Moral R, O'Valle F, Alonso C, Ramiro F, Ortiz - González A, Egido J, Ortiz A. Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. Kidney Int 1997; 51: 1739-46.
38. Chu JL, DrappaJ, Pamassa A, Elkon KB. The defect in Fas mRNA expression in MRL/lpr mice is associated vvith insertion of the retrotransposon, ETn. J Exp Med 1993; 178: 723-30.
39. Booker JK, Reap EA, Cohen PL. Expression and function of Fas on cells damaged by gamma irradiation in B6 and B6/lpr mice. J Immunol 1998; 161: 4536-41.
40. Lee J, Richburg JH, Younkin SC, Boekelheide K. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 1997; 138: 2081-8.
41. Chu JL, Ramos P, Rosendorff A, Nikolic-Zugic J, Lacy E, Matsuzawa A, Elkan KB. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the versus-host disease-like wasting syndrome. J Exp Med 1995; 181: 393-8.
42. Takahashi T, Tanak M, Brannan CI, Jenkins NA, Copeland NG, Suda TS, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-76.
43. Weintraub JP, Eisenberg RA, Cohen PL. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice. J Immunol 1997; 159: 4117.
44. Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA, Schwarz T. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 1998; 140: 171-82.
45. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufinann SH, Gores GJ. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137-45.
46. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
47. Ortiz A, Ganzález-Cuadrado S, Lorz C, Garcia del Moral R, O'Valle F, Egido J. Cytokines and Fas regulate apoptosis in murine renal interstitial fibroblasts. J Am Soc Nephrol 1997; 8: 1845-54.
48. Lorz C, Ortiz A, González-Cuadrado S, Duque N, Gómez-Guerrero C, Egido J. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli Am J Soc Nephrol 1999 (Abstract).
49. Schelling JR, Nkemere N, Kapp JB, Cleveland RP. Fas dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998; 78: 813-24.
50. Wang J, Nonomura N, Ichimaru N, Azuma H, Hatori M, Kokado Y, Matsumiya K, Miki T, Takahara S, Okuyama A. Expression of Fas and Fas ligand in renal grafts with acute and chronic rejection in the rat model. J Interferon Cytokine Res 1997; 17: 369-73.
51. Akasaka Y, Ishikawa Y, Kato S, Ishii T, Masuda T, Fujita K, Yamada T, Kawamura S. Induction of Fas-mediated apoptosis in a human renal epithelial cell line by interferon-gamma: involvement of Fas-mediated apoptosis in acute renal rejection. Mod Pathol 1998; 11: 1107-14.
52. Strehlau J, Pavlakis M, Lipman M, Shapiro M, Vasconcellos L, Hanrmon W, Strom TB. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Nad Acad Sci USA 1997; 94: 695-700.
53. Shalma VK, Bologa RM, Li B, Xu GP, Lagman M, Hiscock W, Mouradian J, Wang J, Serur D, Rao VK, Suthanthiran M. Molecular executors of cell death: differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62: 1860-6.
54. Vasconcellos LM, Asher F, Schachter D, Zheng XX, Vasconcellos LH, Shapiro M, Hannon WE, Strom TB. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66: 562-6.
55. González-Cuadrado S, López-Armada MJ, Gómez-Guerrero C, Subirá D, Ortiz-González A, Neilson EG, Egido J, Ortiz A. Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. Kidney Int 1996; 49: 1064-70.
56. Healy E, Dempsey M, Lally C, Ryan MP. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998; 54: 1955-66.
57. Conaldi PG, Biancone L, Battelli A, Wade-Evans A, Racusen LC, Boccellino M, Orlandi V, Serra C, Camussi G, Toniolo A. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest 1998; 102: 2041.
58. Khan S, Koch C, Schelling JR. Hypoxia induces Fas-dependent tubular cell apaptosis in chronic renal failure. J Am Soc Nephrol 1998; 9: 441A.
59. Yasutomo K, Nagasawa H, Uehara H, Hisaeda H, Kagami S, Okada K, Kuroda Y, Himeno K. The novel regulatory mechanism of Fas system-mediated apoptosis in mesangial cells: implication to mesangial proliferative glomerulonephntis. Biochem Biophys Res Commun 1996; 219: 89-95.
60. Nogae S, Miyazaki M, Kobayashi N, Saito T, Abe K, Saito H, Nakane PK, Nakanishi Y, Koji T. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. J Am Soc Nephrol 1998; 9:620-31.
61. Hattori T, Shindo S, Kawamura H. Apoptosis and expression of Bax protein and Fas antigen in glomeruli of a remnant-kidney model. Nephron 1998; 79: 186-91.
62. Takemura T, Murakami K, Miyazato H, Yagi K, Yoshioka K. Expression of Fas antigen and Bcl-2 in human glomerulonephritis. Kidney Int 1995; 48: 1886-92.
63. Ortiz A, Neilson EG. Expression of bax and bcl-x, members of the bcl-2 gene family, in murine tubular cells and acute renal failure. J Am Soc Nephrol 1994; 5: 906.
64. Spanaus KS, Schlapbach R, Fontana A. TNF-alpha and IFN gamma render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xL. Eur J Immunol 1998; 28: 4398-408.
65. Wever PC, Boonstra M, Laterveer JC, Hack CE, van der Woude FJ, Daha MR, ten Berge IJ. Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 1998; 66: 259-64.
66. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997; 89: 1224-34.
67. Desmouliére A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146: 56-66.
68. Mooney A, Jobson T, Bacon R, Kitamura M, Savill J. Cytokines promote glomerular mesangial cell survival in vitro by stimulus-dependent inhibition of apoptosis. J Immunol 1997; 159: 3949-60.
69. Swenson KM, Ke B, Wang T, Markawitz JS, Maggard MA, Spear GS, Imagawa DK, Goss JA, Busuttil RW, Seu P. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998; 65: 155-60.
70. Vaux DL. Immunology. Ways around rejection. Nature 1998; 394: 133.
71. Kimura M, Mohri H, Shimada K, Wakabayashi T, Kanai Y, Matsuzawa A. Serological and histological characterzation of the new mutant strain of lpr mice, CBA/KlJms-lprcg/lprcg. Clin Exp Immunol 1990; 79: 123-9.
72. Kimura M, Ogata Y, Shimada K, Wakabayashi T, Onoda H, Katagiri T, Matsuzawa A. Nephritogenicity of the lprcg gene on the MRL background. Immunology 1992; 76: 498-504.
73. Wada T, Schwarting A, Kinoshita K, Naito T, Griffiths RC, Coffman TM, Kelley VR. Fas on renal parenchymal cells does not promote autoimmune nephritis in MRL mice. Kidney Int 1999; 55: 841-51.
74. Hughes J, Johnson RJ. The role of Fas (CD95) in unilateral ureteral obstruction. J Am Soc Nephrol 1998; 9: 440A.
75. Fleck M, Kern ER, Zhou T, Podlech J, Wintersberger W, Edward CK, Mountz JD. Apoptosis mediated by fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus. J Clin Invest 1998; 102: 1431-43.
76. Chung CS, Xu YX, Wang W, Chaudry IH, Ayala A. Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? Arch Surg 1998; 133: 1213-20.
77. Heumann D, Le Roy D, Zanetti G, Eugster HP, Ryffel B, Hahne M, Tschopp J, Glauser MP. Contribution of TNF/TNF receptor and of Fas ligand to toxicity in murine models of endotoxemia and bacterial peritonitis. J Inflamm 1995-96; 47: 173-9.
78. Strutz F, Okada H, Lo CW, Danoff T, Carone B, Tomaszewski J, Neilson EG. Identification and characterization of a new fibroblast specific marker: FSP-1. J Cell Biol 1995; 130: 393-406.